
AINIA highlights why fermented foods are not automatically probiotics, using Spain’s proposed kefir standard to examine labels and evidence.

In an article published on 10 November 2026, AINIA highlighted opportunities for functional foods made with prebiotics, probiotics and postbiotics. It emphasized that these categories have distinct scientific requirements and that fermentation alone does not establish probiotic or postbiotic status.
The scientific framework behind AINIA’s discussion was already in place. Its article applies established definitions rather than announcing a new understanding of how all fermented foods affect health. Those definitions distinguish what a product contains from the evidence supporting its claimed benefit.
AINIA describes a prebiotic as a substrate selectively used by the body’s microorganisms that confers a health benefit. In plain language, the material must be used by particular microorganisms and provide a benefit to the person.
That is why not all dietary fibres qualify as prebiotics. Fibre content and prebiotic status describe different things. According to AINIA’s explanation, identifying an ingredient as fibre does not by itself establish the selective use and health benefit required for the prebiotic label.
The US National Institutes of Health Office of Dietary Supplements gives the established probiotic definition: live microorganisms that confer a health benefit when administered in adequate amounts. Being alive is part of the definition, but it is not the whole definition.
The NIH office also notes that not all fermented foods with live cultures contain probiotic microorganisms. A live-culture statement describes something about the food’s contents. It does not automatically answer whether those microorganisms meet the requirements for a probiotic.
AINIA describes a postbiotic as a preparation of inanimate microorganisms and/or their components that confers a health benefit. Inanimate means the microorganisms are no longer alive.
Simply inactivating microorganisms does not establish postbiotic status. AINIA says the starting microorganisms and production process must be characterised. Safety must also be addressed, and evidence must support the health benefit of the resulting preparation.
Keeping these ingredient categories distinct provides a foundation for interpreting product descriptions. Similar names do not make the categories interchangeable.
The development highlighted by AINIA is not a replacement for those definitions. It is greater attention to how ingredients are identified and formulated, alongside the evidence used to support claims. The proposed Spanish kefir standard gives that discussion a concrete example.
AINIA reports that Spain’s Ministry of Agriculture, Fisheries and Food opened a preliminary consultation in October 2026 on a proposed first specific quality standard for kefir. The proposed scope covered production and marketing as well as designation and labelling. Comments were due by 30 October.
For readers, this brings two separate questions into view. What requirements should a food meet to be sold under a particular name? What evidence supports a statement about its health effects?
A product-identity standard addresses the first question. The definitions of probiotics and postbiotics introduce additional requirements concerning a health benefit. Understanding the difference helps keep a familiar food name separate from a stronger scientific claim.
AINIA says the properties of one strain cannot automatically be extrapolated to another strain, even within the same species. This makes the exact microorganism relevant when a product description connects a probiotic to a particular function.
The useful comparison is therefore more specific than whether two products both use the word “probiotic.” It asks whether the microorganism and strain are identified and whether the claimed function is supported for that strain. A broad category name does not provide all of that information.
AINIA identifies advanced fermentation, microencapsulation and in-vitro digestion models as tools used in ingredient and product development. It also describes several requirements that formulation work must address:
These are product-development considerations, not directions for choosing a personal supplement dose. They show why naming a promising ingredient is only part of developing a finished food.
AINIA says postbiotics may be easier to incorporate into some foods when processing or storage conditions threaten probiotic viability. It nevertheless stresses that stability and functionality require evaluation for each formulation. This is a manufacturing consideration rather than evidence that postbiotics are universally more effective or preferable for consumers.
AINIA reports that Mintel’s Biotics: Deliver Targeted and Personalised Ingredients found that 63% of surveyed consumers who use, or might use, gut-health products considered explanations of probiotic strain functions important.
The same AINIA article attributes another finding to Mintel: 56% of surveyed digestive-health-product users found it difficult to know whether products were working or symptoms had improved naturally.
These findings place a consumer question beside the technical work: what exactly is a product supposed to do? A specific explanation connects the claimed function to the ingredient being discussed. General language about gut health leaves that connection less clear.
AINIA also distinguishes research on ingredient functionality from the separate requirements governing health-benefit claims in food labelling and advertising under European legislation. Investigating a possible function and substantiating a permitted marketing claim are related tasks, but they are not identical.
AINIA’s article brings together definitions, development work and market observations. It is not a clinical trial establishing that a finished product relieves bloating or irregularity. The sources do not establish that a particular biotic product will improve an individual reader’s digestive symptoms.
Its research examples illustrate the stage of work being discussed. AINIA says BIOPROSPECT isolated more than 100 microbial strains from natural environments for investigation. That describes research material, not a collection of clinically proven probiotics.
AINIA also describes DISBIOSIS as developing experimental in-vitro models of changes in gut microbiota. In-vitro research takes place outside the human body. An organ-on-chip system in this work integrates aspects of gastrointestinal digestion, colonic microbiota and intestinal mucosa, which is the intestinal lining.
These models can support investigation, but AINIA explicitly says they do not replace relevant human clinical trials. It makes a related distinction about tests of resistance to acidic pH and bile salts: these can help identify candidate strains but do not by themselves demonstrate a health benefit.
The reported Mintel percentages also need a defined boundary. AINIA’s accessible article does not provide the survey sample size, field dates or complete methodology. The figures describe the surveyed groups as reported by AINIA and should not be generalised to all consumers.
Finally, the kefir consultation was a proposal rather than an adopted standard. The reviewed sources establish a consultation and its comment deadline. They do not establish the final wording or legal effect of a completed regulation.
For everyday food choices, the practical response is to read these descriptions separately. “Fermented” and “contains live cultures” describe features of a food. Probiotic and postbiotic descriptions bring requirements for evidence of a health benefit.
When comparing products, useful questions concern the identified microorganism or preparation and the specific function being claimed. For probiotics, strain information matters. Reading evidence by the intended purpose is more informative than treating the category name as a general promise of better digestion.
Persistent or recurring digestive concerns belong in a discussion with a qualified healthcare professional rather than being treated as a reason to select a product from its label alone.
AINIA’s article supports more precise interpretation of food and supplement claims. It does not call for abandoning fermented foods or redesigning every meal around a biotic label.
Treating every fermented food as a probiotic turns a product description into an unsupported health promise. DigestGenius addresses the resulting uncertainty about biotic ingredients through no-cost articles and detailed educational resources on digestion and nutrition, giving adults evidence-aware context for confusing probiotic and supplement claims without presenting one approach as suitable for everyone.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog